ULTRASOUND AND TISSUE REPAIR

• US 20090216158A1
• Filed: 02/20/2009
• Published: 08/27/2009
• Est. Priority Date: 02/22/2008
• Status: Abandoned Application

• Current Assignee: Bioventus LLC
• Original Assignee: Bioventus LLC
• Inventors: BASS, MARK, HARRISON, ANDREW JAMES, HUMPHRIES, MARTIN, MAHONEY, CLAIRE
• Application Number:
  US12/390,065
• Publication Number:
  US 20090216158A1
• Time in Patent Office: Days
• US Class Current: 601/2
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

Methods of using an ultrasound signal to promote tissue repair by causing cells to form focal adhesions without the involvement of syndecans, in particular syndecan-1, syndecan-4 or PKCα are disclosed.

Claims

1. A method of activating a member of the Rho kinase family in a subject by exposing the subject to an ultrasound signal.

2. The method according to claim 1, wherein the Rho kinase is GTPase Rac1.

3. The method according to claim 1, wherein the ultrasound signal is pulsed.

4. The method according to claim 3, wherein the ultrasound signal has a pulse frequency of 1 KHz.

5. The method according to claim 1, wherein the ultrasound signal has an intensity of at least 25 mWcm-2.

6. The method according to claim 1, wherein the ultrasound signal has a 1.5 MHz wave frequency.

7. The method according to claim 1, wherein the subject is exposed to the ultrasound for at least an 8 minute period.

8. The method according to claim 7, wherein the subject is human.

10. The method according to claim 8, wherein the ultrasound signal is pulsed.

12. The method according to claim 8, wherein the ultrasound signal has an intensity of at least 25 mWcm-2.

13. The method according to claim 8, wherein the ultrasound signal has a 1.5 MHz wave frequency.

14. The method according to claim 8, wherein the subject is exposed to the ultrasound for at least an eight minute period.

15. The method according to claim 8, wherein the subject is human.

9. A method of promoting tissue repair in a subject by activating GTPase Rac1, the method comprising the step of exposing the tissue to an ultrasound signal.

11. The method according to claim 9, wherein the ultrasound signal has a pulse frequency of 1 KHz.

16. A method of promoting the formation of focal adhesions in a subject by exposing the subject to an ultrasound signal.

17. The method according to claim 16, wherein the ultrasound signal is pulsed.

18. The method according to claim 17, wherein the ultrasound signal has a pulse frequency of 1 KHz.

19. The method according to claim 16, wherein the ultrasound signal has an intensity of at least 25 mWcm-2.

20. The method according to claim 16, wherein the ultrasound signal has a 1.5 MHz wave frequency.

21. The method according to claim 16, wherein the subject is exposed to the ultrasound for at least an eight minute period.

22. The method according to claim 16, wherein the subject is human.

23. A method of determining the likelihood of a deficient wound healing response in an individual, the method comprising the steps of:

a. determining the concentration of a syndecan in a sample of bodily fluid taken from an individual;

b. comparing the concentration with a predetermined cut-off value, said cut-off value being chosen to exclude concentrations of a syndecan associated with an optimal wound healing response in an individual, wherein a concentration below the cut-off value is indicative of the likelihood of a sub-optimal wound healing response.

24. The method according to claim 23, wherein the syndecan is syndecan-1 and/or syndecan-4.

25. A method of enhancing the wound healing response in an individual, the method comprising the steps of:

a. determining the concentration of a syndecan in a sample of bodily fluid taken from an individual;

b. comparing the concentration with a pre-determined cut-off value, said cut-off value being chosen to exclude concentrations of a syndecan associated with an optimal wound healing response in an individual, wherein a concentration below the cut-off value is indicative of the likelihood of a sub-optimal wound healing response; and

c. exposing the wound to ultrasound if the concentration of a syndecan in the bodily fluid is below the cut-off value.

26. The method according to claim 25, wherein the syndecan is syndecan-1 and/or syndecan-4.

27. A method of determining the likelihood of a deficient wound healing response in an individual, the method comprising the steps of:

a. determining the concentration of a PKCα

in a sample of bodily fluid taken from an individual; and

b. comparing the concentration with a pre-determined cut-off value, said cut-off value being chosen to exclude concentrations of a PKCα

associated with an optimal wound healing response in an individual, wherein a concentration below the cut-off value is indicative of the likelihood of a sub-optimal wound healing response.

28. A method of enhancing the wound healing response in an individual, the method comprising the steps of:

a. determining the concentration of a PKCα

in a sample of bodily fluid taken from an individual;

b. comparing the concentration with a pre-determined cut-off value, said cut-off value being chosen to exclude concentrations of a PKCα

associated with an optimal wound healing response in an individual, wherein a concentration below the cut-off value is indicative of the likelihood of a sub-optimal wound healing response; and

c. exposing the wound to ultrasound if the concentration of a PKCα

in the bodily fluid is below the cut-off value.